Johnson & Johnson-backed HistoSonics, a developer of sonic beams that attack tumours, is pursuing a sale after fielding takeover bids from several suitors, said people familiar with the matter. HistoSonics, which makes a non-invasive ultrasound treatment for the most aggressive form of liver cancer, is seeking a valuation of more than $2.5bn, one of the people said. Medical device manufacturers including Medtronic, GE HealthCare and Johnson & Johnson, which already holds a stake in the privately held group, are evaluating the business, they added. Other suitors could emerge.
Read the full article: J&J-Backed Developer of Tumour-Targeting ‘Sonic Beam’ HistoSonics Fields Takeover Offers //
Source: https://www.ft.com/content/cb1c5bf1-ddf8-4c8b-b62d-99c081bce8c6